{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:02:39Z","timestamp":1792458159672,"version":"4.5.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"9","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening, hyperinflammatory syndrome. Emapalumab, a fully human monoclonal antibody that neutralizes the proinflammatory cytokine interferon gamma, is approved in the United States to treat primary HLH (pHLH) in patients with refractory, recurrent, or progressive disease, or intolerance with conventional HLH treatments. REAL-HLH, a retrospective study, conducted across 33 US hospitals, evaluated real-world treatment patterns and outcomes in patients treated with \u22651 dose of emapalumab between 20 November 2018 and 31 October 2021. In total, 46 patients met the pHLH classification criteria. Median age at diagnosis was 1.0 year (range, 0.3-21.0). Emapalumab was initiated for treating refractory (19\/46), recurrent (14\/46), or progressive (7\/46) pHLH. At initiation, 15 of 46 patients were in the intensive care unit, and 35 of 46 had received prior HLH-related therapies. Emapalumab treatment resulted in normalization of key laboratory parameters, including chemokine ligand 9 (24\/33, 72.7%), ferritin (20\/45, 44.4%), fibrinogen (37\/38, 97.4%), platelets (39\/46, 84.8%), and absolute neutrophil count (40\/45, 88.9%). Forty-two (91.3%) patients were considered eligible for transplant. Pretransplant survival was 38 of 42 (90.5%). Thirty-one (73.8%) transplant-eligible patients proceeded to transplant, and 23 of 31 (74.2%) of those who received transplant were alive at the end of the follow-up period. Twelve-month survival probability from emapalumab initiation for the entire cohort (N = 46) was 73.1%. There were no discontinuations because of adverse events. In conclusion, results from the REAL-HLH study, which describes treatment patterns, effectiveness, and outcomes in patients with pHLH treated with emapalumab in real-world settings, are consistent with the emapalumab pivotal phase 2\/3 pHLH trial.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012217","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T02:28:55Z","timestamp":1709346535000},"page":"2248-2258","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":37,"title":["Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab"],"prefix":"10.1182","volume":"8","author":[{"given":"Shanmuganathan","family":"Chandrakasan","sequence":"first","affiliation":[{"name":"1Division of Bone Marrow Transplant, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Jordan","sequence":"additional","affiliation":[{"name":"2Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH"},{"name":"3Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2327-7972","authenticated-orcid":false,"given":"Ashley","family":"Baker","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, Division of Hematology Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Behrens","sequence":"additional","affiliation":[{"name":"5Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Bhatla","sequence":"additional","affiliation":[{"name":"6Department of Pediatric Hematology Oncology, Saint Louis University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Chien","sequence":"additional","affiliation":[{"name":"7Department of Hematology-Oncology, Lucile Packard Children's Hospital at Stanford University, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olive S.","family":"Eckstein","sequence":"additional","affiliation":[{"name":"8Division of Pediatric Hematology and Oncology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3624-0706","authenticated-orcid":false,"given":"Michael M.","family":"Henry","sequence":"additional","affiliation":[{"name":"9Department of Pediatric Hematology-Oncology, Phoenix Children\u2019s, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1790-2679","authenticated-orcid":false,"given":"Michelle L.","family":"Hermiston","sequence":"additional","affiliation":[{"name":"10Department of Pediatric Hematology-Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley P.","family":"Hinson","sequence":"additional","affiliation":[{"name":"11Department of Pediatric Hematology-Oncology, Atrium Health, Levine Children's Hospital, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7573-9390","authenticated-orcid":false,"given":"Jennifer W.","family":"Leiding","sequence":"additional","affiliation":[{"name":"12Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiola","family":"Oladapo","sequence":"additional","affiliation":[{"name":"13Medical Affairs, Sobi Inc, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachit A.","family":"Patel","sequence":"additional","affiliation":[{"name":"14Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Pednekar","sequence":"additional","affiliation":[{"name":"15HEOR Division, PRECISIONheor, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish K.","family":"Ray","sequence":"additional","affiliation":[{"name":"16Department of Pediatric Hematology-Oncology, Cook Children's Medical Center, Fort Worth, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8281-3627","authenticated-orcid":false,"given":"Blachy","family":"D\u00e1vila Salda\u00f1a","sequence":"additional","affiliation":[{"name":"17Division of Blood and Marrow Transplantation, Children's National Medical Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmita N.","family":"Sarangi","sequence":"additional","affiliation":[{"name":"18Department of Pediatric Hematology-Oncology, MedStar Georgetown University Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Walkovich","sequence":"additional","affiliation":[{"name":"19Division of Pediatric Hematology\/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Yee","sequence":"additional","affiliation":[{"name":"13Medical Affairs, Sobi Inc, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Zoref-Lorenz","sequence":"additional","affiliation":[{"name":"2Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH"},{"name":"20Division of Hematology, Hematology Institute, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E.","family":"Allen","sequence":"additional","affiliation":[{"name":"8Division of Pediatric Hematology and Oncology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"2024051415215069700_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/asheducation-2015.1.177","article-title":"Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis","volume":"2015","author":"Allen","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2024051415215069700_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1651-2227.1991.tb11878.x","article-title":"Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis","volume":"80","author":"Henter","year":"1991","journal-title":"Acta Paediatr Scand"},{"issue":"15","key":"2024051415215069700_bib3","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2024051415215069700_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41572-021-00307-9","article-title":"Histiocytic disorders","volume":"7","author":"McClain","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"2024051415215069700_bib5","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/bcp.15133","article-title":"Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: a pharmacometric model-based approach","volume":"88","author":"Jacqmin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2024051415215069700_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2024051415215069700_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.blre.2014.03.002","article-title":"Hemophagocytic syndromes--an update","volume":"28","author":"Janka","year":"2014","journal-title":"Blood Rev"},{"issue":"2","key":"2024051415215069700_bib8","first-page":"197","article-title":"Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society","volume":"10","author":"Aric\u00f2","year":"1996","journal-title":"Leukemia"},{"key":"2024051415215069700_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-041610-134208","article-title":"Familial and acquired hemophagocytic lymphohistiocytosis","volume":"63","author":"Janka","year":"2012","journal-title":"Annu Rev Med"},{"issue":"11","key":"2024051415215069700_bib10","doi-asserted-by":"crossref","first-page":"e27929","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO)","volume":"66","author":"Jordan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2024051415215069700_bib11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2024051415215069700_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/emmm.200900009","article-title":"Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice","volume":"1","author":"Pachlopnik Schmid","year":"2009","journal-title":"EMBO Mol Med"},{"issue":"4","key":"2024051415215069700_bib13","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jaci.2017.07.021","article-title":"Neutralization of IFN-\u03b3 reverts clinical and laboratory features in a mouse model of macrophage activation syndrome","volume":"141","author":"Prencipe","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"2024051415215069700_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.trsl.2016.07.023","article-title":"Use of a mouse model to identify a blood biomarker for IFN\u03b3 activity in pediatric secondary hemophagocytic lymphohistiocytosis","volume":"180","author":"Buatois","year":"2017","journal-title":"Transl Res"},{"issue":"6","key":"2024051415215069700_bib15","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.jaci.2018.10.068","article-title":"IFN-\u03b3 and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis","volume":"143","author":"Humblet-Baron","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"2024051415215069700_bib16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jpeds.2011.11.046","article-title":"Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children","volume":"160","author":"Xu","year":"2012","journal-title":"J\u00a0Pediatr"},{"issue":"17","key":"2024051415215069700_bib17","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/bloodadvances.2021004287","article-title":"IFN-gamma signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS","volume":"5","author":"Lin","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2024051415215069700_bib18","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/rheumatology\/keu524","article-title":"Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-\u03b3","volume":"54","author":"Put","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2024051415215069700_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1365-2249.2003.02237.x","article-title":"Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis","volume":"133","author":"Takada","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"2024051415215069700_bib20","doi-asserted-by":"crossref","first-page":"850443","DOI":"10.3389\/fimmu.2022.850443","article-title":"Simple evaluation of clinical situation and subtypes of pediatric hemophagocytic lymphohistiocytosis by cytokine patterns","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"2024051415215069700_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2016.05.022","article-title":"Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis","volume":"85","author":"Yang","year":"2016","journal-title":"Cytokine"},{"issue":"3","key":"2024051415215069700_bib22","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2021.07.031","article-title":"Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders","volume":"149","author":"Marsh","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"2024051415215069700_bib23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.bbmt.2018.01.022","article-title":"Outcomes of children with hemophagocytic lymphohistiocytosis given allogeneic hematopoietic stem cell transplantation in Italy","volume":"24","author":"Messina","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2024051415215069700_bib24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/(SICI)1096-911X(199705)28:5<342::AID-MPO3>3.0.CO;2-H","article-title":"HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society","volume":"28","author":"Henter","year":"1997","journal-title":"Med Pediatr Oncol"},{"issue":"25","key":"2024051415215069700_bib25","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"key":"2024051415215069700_bib26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/TCRM.S195538","article-title":"Clinical management of relapsed\/refractory hemophagocytic lymphohistiocytosis in adult patients: a review of current strategies and emerging therapies","volume":"17","author":"Yildiz","year":"2021","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"2024051415215069700_bib27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.cyto.2012.06.257","article-title":"Investigating the novel mechanism of action for NI-0501, a human interferon gamma monoclonal antibody","volume":"59","author":"Hatterer","year":"2012","journal-title":"Cytokine"},{"issue":"19","key":"2024051415215069700_bib28","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"2024051415215069700_bib29","doi-asserted-by":"crossref","first-page":"102143","DOI":"10.1016\/j.eclinm.2023.102143","article-title":"Orakzai A, Jamshed S. Epidemiology, characteristics, and outcomes of adult haemophagocytic lymphohistiocytosis in the USA, 2006-19: a national, retrospective cohort study","volume":"62","author":"Abdelhay","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2024051415215069700_bib30","volume-title":"GAMIFANT (emapalumab-lzsg) injection, for intravenous use","year":"2022"},{"issue":"2","key":"2024051415215069700_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol Cell Biol"},{"issue":"S1","key":"2024051415215069700_bib32","first-page":"e30097","article-title":"Etoposide for primary HLH - better than its reputation","volume":"70","author":"Lehmberg","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"2024051415215069700_bib33","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol","volume":"118","author":"Trottestam","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2024051415215069700_bib34","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter","year":"2002","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2248\/2224952\/blooda_adv-2023-012217-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2248\/2224952\/blooda_adv-2023-012217-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T15:22:46Z","timestamp":1715700166000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/9\/2248\/515173\/Real-world-treatment-patterns-and-outcomes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012217","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]}}}